Infusional C-myb ASODN in Advanced Hematologic Malignancies

NCT00780052 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: c-myb AS ODN

Sponsor

Abramson Cancer Center at Penn Medicine